Trilaciclib Decreases Rates of High-Grade HAEs in ES-SCLC in RWS

Image Credit: © catalin - www.stock.adobe.com

Treatment with trilaciclib (Cosela) may lower cases of single and multilineage grade 3 myelosuppressive hematologic adverse events (HAEs) as well as cytopenia-related healthcare utilization in patients with extensive-stage small cell lung cancer (ES-SCLC), real-world evidence shows.¹

"Our study evaluated real-world outcomes of patients using data from published and unpublished studies of trilaciclib and comparable non-trilaciclib-treated patients," said Lowell Hart, MD, FACP, a medical oncologist/hematologist at Florida Cancer Specialists & Research Institute, in a press release.² "We found this therapy to be a promising new treatment for chemotherapy-induced myelosuppression (CIM) prevention and with the potential for additional benefits."

In total, 5 studies were reviewed after being accessed through 8 records, including the iKM network, non-iKM networks, Florida Cancer Specialist & Research Institute (FCS), and Integra Connect. A total 137 patients were included in the pooled data.

Results showed that the weighted average prevalence of grade ≥ 3 myelosuppressive HAEs in patients with ≥ 1 lineage was 40.5%. Among patients with ≥ 2 lineages, the prevalence of grade ≥ 3 myelosuppressive HAEs was 14.5%. In patients with all 3 lineages, the prevalence of grade ≥ 3 myelosuppressive HAEs was 7.5%. The rates in all 3 cohorts were numerically better than historic controls in non-trilaciclib cohorts, which respectively showed a prevalence of 58.5%, 28.0%, and 13.0%.

Further, 43.8% of patients had cytopenia-related healthcare utilization. The most common form of healthcare utilization was the receipt of IV hydration, which all patients needed. Patients also required red blood cell transfusions (15.3%), platelet transfusions (0.7%), and erythropoietin stimulating agents (19.7%).

The findings suggest that trilaciclib (Cosela) before administering topotecan can improve chemotherapy outcomes. These findings are consistent with data from clinical trials, which demonstrate the dexterity of trilaciclib in ES-SCLC. Hart et al believe comparative studies with a larger number of patients are needed to provide more in-depth information about the effectiveness of trilaciclib in ES-SCLC.

"FCS continues to be at the forefront of game-changing clinical discoveries that are bringing new hope for cancer patients,” Lucio Gordon, MD, president and managing physician at FCS, in the press release.² "The size of our practice, having nearly 100 locations, is a large contributor to the research being conducted by our physicians, providing a generous pool of patients and data, a pillar in our continued efforts to advance oncology care."

_REFERENCES:

_{1. Goldschmidt J, Hart L, Scott J, et al. Real-World outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy. Adv Ther. Published July 25, 2023. doi: 10.1007/s12325-023-02601-2.}

_{2. Study confirms effectiveness of trilaciclib for treatment of patients with extensive-stage small cell lung cancer co-authored by Florida Cancer Specialists & Research Institute physicians and senior leaders. News release. July 31, 2023. Accessed September 8, 2023. https://tinyurl.com/2p8d5uce}